BioNTech closes Singapore manufacturing plant as COVID-19 vaccine demand collapses

SINGAPORE—BioNTech is shutting down its Singapore manufacturing facility and regional headquarters, marking a dramatic shift from the company’s pandemic-era expansion strategy.

The German mRNA specialist purchased the facility from Novartis during the height of COVID-19 in 2022, but the ongoing decline in vaccine revenues has prompted the company to reassess its global operations.

Strategic realignment

The company confirmed this week that it will close the Singapore site by the end of February 2027.

According to BioNTech’s statement, the decision follows a comprehensive strategic review aimed at aligning the company’s manufacturing capacity with its clinical pipeline and long-term business direction.

The move reflects a broader trend affecting the entire mRNA vaccine sector, as companies grapple with sharply reduced demand for COVID-19 shots in the post-pandemic era.

BioNTech’s situation mirrors the challenges facing its major partner, Pfizer, and competitor Moderna, both of which have seen significant declines in vaccine-related revenue.

The company’s financial trajectory illustrates this downturn starkly: in 2022, BioNTech generated 17.3 billion euros (USD$19.3 billion) in sales, largely driven by its blockbuster Comirnaty vaccine, developed with Pfizer.

By 2025, total company revenues had plummeted to 2.9 billion euros (USD$3.3 billion).

Managing resources strategically

Despite the closure, BioNTech remains committed to cost-effective operations across its business.

The company emphasizes that it actively manages its entire pipeline and evaluates all facilities based on three key criteria: strategic alignment, operational efficiency, and sustainable value creation.

Management intends to continue investing heavily in key parts of the business while improving efficiency in other areas, indicating that this shutdown is part of a careful restructuring rather than a complete withdrawal.

The Singapore facility originally represented an ambitious expansion vision.

BioNTech announced its acquisition by Novartis in November 2022, with plans to establish a regional manufacturing hub in Singapore’s Tuas Biomedical Park.

Once fully operational by late 2023, company leaders projected the plant would manufacture several hundred million mRNA vaccine doses annually, positioning BioNTech as a major player in Asia-Pacific vaccine production.

Employment and future direction

The closure affects approximately 85 employees currently working at the Singapore site. BioNTech plans to offer affected workers severance packages and outplacement support, demonstrating commitment to its workforce during the transition period.

Looking ahead, BioNTech faces leadership uncertainty following the March announcement that co-founders and executives Uğur Şahin and Özlem Türeci will depart by year’s end to establish a new company focused on next-generation mRNA innovations.

Despite recent commercial headwinds, BioNTech continues to pursue its ambitious goal of becoming a fully integrated immunotherapy powerhouse, with multiple late-stage oncology programs advancing through its development pipelines.